137 related articles for article (PubMed ID: 36787734)
1. SARS-CoV-2 Incubation Period during the Omicron BA.5-Dominant Period in Japan.
Ogata T; Tanaka H
Emerg Infect Dis; 2023 Mar; 29(3):595-598. PubMed ID: 36787734
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan (Response).
Ogata T; Tanaka H
Emerg Infect Dis; 2024 Jan; 30(1):207. PubMed ID: 38146992
[No Abstract] [Full Text] [Related]
3. SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan.
Cheng HY; Akhmetzhanov AR; Dushoff J
Emerg Infect Dis; 2024 Jan; 30(1):206-207. PubMed ID: 38146985
[No Abstract] [Full Text] [Related]
4. Serial Intervals and Incubation Periods of SARS-CoV-2 Omicron and Delta Variants, Singapore.
Zeng K; Santhya S; Soong A; Malhotra N; Pushparajah D; Thoon KC; Yeo B; Ho ZJM; Cheng MCI
Emerg Infect Dis; 2023 Apr; 29(4):814-817. PubMed ID: 36878009
[TBL] [Abstract][Full Text] [Related]
5. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
7. Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
Xu X; Wu Y; Kummer AG; Zhao Y; Hu Z; Wang Y; Liu H; Ajelli M; Yu H
BMC Med; 2023 Sep; 21(1):374. PubMed ID: 37775772
[TBL] [Abstract][Full Text] [Related]
8. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant.
Tanaka H; Ogata T; Shibata T; Nagai H; Takahashi Y; Kinoshita M; Matsubayashi K; Hattori S; Taniguchi C
Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627870
[TBL] [Abstract][Full Text] [Related]
9. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain.
Del Águila-Mejía J; Wallmann R; Calvo-Montes J; Rodríguez-Lozano J; Valle-Madrazo T; Aginagalde-Llorente A
Emerg Infect Dis; 2022 Jun; 28(6):1224-1228. PubMed ID: 35393009
[TBL] [Abstract][Full Text] [Related]
10. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
Xu R; Wang W; Zhang W
Front Public Health; 2022; 10():1039123. PubMed ID: 36504951
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of incubation periods of infections of Omicron variants BA.2 and BF.7 in Beijing].
Xu X; Cai YX; Liu YH; Shen Y; Pan Y; Yao H; Wang XL; Yang P
Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Sep; 44(9):1397-1401. PubMed ID: 37743272
[No Abstract] [Full Text] [Related]
12. Shorter Incubation Period among Unvaccinated Delta Variant Coronavirus Disease 2019 Patients in Japan.
Ogata T; Tanaka H; Irie F; Hirayama A; Takahashi Y
Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162151
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants.
Ali KM; Rashid PMA; Ali AM; Tofiq AM; Salih GF; Dana OI; Rostam HM
Eur J Clin Invest; 2023 Sep; 53(9):e14004. PubMed ID: 37036255
[TBL] [Abstract][Full Text] [Related]
14. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice.
Baz M; Deshpande N; Mackenzie-Kludas C; Mordant F; Anderson D; Subbarao K
Emerg Infect Dis; 2022 Nov; 28(11):2352-2355. PubMed ID: 36191630
[TBL] [Abstract][Full Text] [Related]
16. Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants.
Madewell ZJ; Yang Y; Longini IM; Halloran ME; Vespignani A; Dean NE
BMC Infect Dis; 2023 Jun; 23(1):429. PubMed ID: 37365505
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of SARS-CoV-2 Omicron BA.5 Infections, Macau, June-July 2022.
Xiong W; Peng L; Tsang TK; Cowling BJ
Emerg Infect Dis; 2023 Feb; 29(2):453-456. PubMed ID: 36648122
[TBL] [Abstract][Full Text] [Related]
18. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
[TBL] [Abstract][Full Text] [Related]
19. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
[TBL] [Abstract][Full Text] [Related]
20. Comparing the incubation period, serial interval, and infectiousness profile between SARS-CoV-2 Omicron and Delta variants.
Guo Z; Zhao S; Mok CKP; So RTY; Yam CHK; Chow TY; Chan TCP; Wei Y; Jia KM; Wang MH; Chong KC; Yeoh EK
J Med Virol; 2023 Mar; 95(3):e28648. PubMed ID: 36892159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
